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Abstract:  
Background & Aims: Alterations in signaling pathways that regulate resolution of 
inflammation (resolving pathways) contribute to pathogenesis of ulcerative colitis (UC). The 
resolution process is regulated by lipid mediators, such as those derived from the ω-3 
docosahexaenoic acid (DHA), whose esterified form is transported by the major facilitator 
superfamily domain containing 2A (MFSD2A) through the endothelium of brain, retina, and 
placenta. We investigated if and how MFSD2A regulates lipid metabolism of gut endothelial 
cells to promote resolution of intestinal inflammation. 
 
Methods: We performed lipidomic and functional analyses of MFSD2A in mucosal biopsies 
and primary human intestinal microvascular endothelial cells (HIMECs) isolated from surgical 
specimens from patients with active, resolving UC and healthy individuals without UC 
(controls). MFSD2A was knocked down in HIMECss with small hairpin RNAs or 
overexpressed from a lentiviral vector. Human circulating endothelial progenitor cells that 
overexpress MFSD2A were transferred to CD1 nude mice with dextran sodium sulfate-
induced colitis, with or without oral administration of DHA. 
 
Results: Colonic biopsies from patients with UC had reduced levels of inflammation-resolving 
DHA-derived epoxy metabolites compared to healthy colon tissues or tissues with resolution 
of inflammation. Production of these metabolites by HIMECs required MFSD2A, which is 
required for DHA retention and metabolism in the gut vasculature. In mice with colitis, 
transplanted endothelial progenitor cells that overexpressed MFSD2A not only localized to the 
inflamed mucosa but also restored the ability of the endothelium to resolve intestinal 
inflammation, compared to mice with colitis that did not receive MFSD2A-overexpressing 
endothelial progenitors  
 
Conclusions: Levels of DHA-derived epoxides are lower in colon tissues from patients with 
UC than healthy and resolving mucosa. Production of these metabolites by gut endothelium 
requires MFSD2A; endothelial progenitor cells that overexpress MFSD2A reduce colitis in 
mice. This pathway might be induced to resolve intestinal inflammation in patients with colitis. 
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Introduction 
Ulcerative colitis (UC) is a long-term idiopathic inflammatory disorder affecting the colon and 
rectum, whose prevalence and incidence is rapidly increasing worldwide, and whose medical 
treatments have only been mildly successful1. For many years, dysregulations in inflammatory 
pathways have been considered as the basis of UC pathogenesis; nevertheless, the simple 
targeting of infiltrating immune cells and their products to control inflammation does not 
always lead to remission. New evidences indicate that a failure in resolving pathways might 
also contribute to the pathogenesis of this disease2,3. Indeed, only recently the resolution of 
inflammation has been conclusively recognized as an active process orchestrated by 
resolving lipid mediators, which dampen inflammation-sustaining events, such as 
angiogenesis, release of inflammatory cytokines, clearance of apoptotic cells and 
microorganisms4,5. Among these resolving molecules, those derived from essential ω-3-
polyunsaturated fatty acids (PUFAs), have been shown to exert beneficial effects on a wide 
range of human inflammatory disorders, including UC6. In particular, epoxy metabolites of 
docosahexaenoic acid (DHA), generated by cytochrome P-450 (CYP450) enzymes, promote 
potent biological activities in the regulation of vascular, pulmonary, cardiac and intestinal 
functions7,8.  
The progression of chronic intestinal inflammation is not only orchestrated by immune cells, 
but also non-immune cells, and particularly by endothelial cells. In fact, UC patients are 
characterized by increased vascularization and excessive release of angiogenic factors9. The 
ability of endothelial cells to secrete anti-inflammatory mediators, which help to coordinate 
leukocyte trafficking and maintain barrier function, renders them crucial players in the 
resolution of inflammation10. Seminal studies have pointed out the pro-resolving beneficial 
effects of ω-3 DHA on endothelial cells under inflammatory conditions8,11. Although the 
endothelium plays a major role in resolution of inflammation, the exact mechanisms behind 
this process are still unknown, particularly in the gastrointestinal tract. The endothelial 
lysophosphatidylcholine transporter, namely the major facilitator superfamily domain 
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containing 2A (MFSD2A), has recently been shown to be essential for DHA uptake in the 
blood brain barrier, eye and placenta12–14. Here we elucidate a significant role for MFSD2A in 
the maintenance of the balance between inflammatory and resolving epoxy metabolites of 
DHA in intestinal microvasculature and how this could be used for the development of novel 
therapeutic strategies to treat UC.  
 
Material and methods 
Detailed protocols are provided in the Supplementary Material and Methods.  
Results 
Lipid signature of intestinal mucosa from patients with active UC highlights defects in 
DHA metabolite production 
PUFAs are known to regulate the duration and magnitude of inflammation, with ω-6 fatty 
acids mostly as inflammatory and ω-3 fatty acids as resolving molecules15. In order to define 
the fatty acyl signature of patients with UC, endoscopic biopsies collected from the colon of 
actively inflamed, and resolving patients, including healthy tissues (Supplementary Table 1 
for patient characteristics), were characterized by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Lipid mediators were classified on the basis of their precursors: ω-
6 Arachidonic Acid (AA), Dihomo-γ-linolenic Acid (DGLA) and Linoleic Acid (LA), and the ω-3 
DHA, Eicosapentaenoic Acid (EPA) and Linolenic Acid (LNA). Principal components analysis 
(PCA) performed on LC-MS/MS data output highlighted a distinct lipid signature of actively 
inflamed biopsies, while healthy tissues and tissues with resolution of inflammation (resolving 
tissues) did not cluster (Figure 1A). Beside, a volcano plot revealed that the inflamed mucosa 
was significantly enriched in ω-6 AA-derived lipid mediators, in comparison with both healthy 
(Figure 1B) and resolving tissues (Figure 1C), with significantly reduced levels of lipid 
mediators derived from other precursors, including DHA-derived metabolites (Figure 1B and 
C).  We next evaluated the contribution of metabolites from the various lipid precursors to the 
total composition of lipid mediators. Results showed that while AA-derived metabolites were 
increased in active mucosa (Figure 1D and E), the amount of docosanoids was significantly 
reduced (Figure 1D and F), in comparison with healthy and remission groups, with no 
differences in the contribution of mediators from other lipid classes, such as EPA and LNA 
(Supplementary Figure 1A and B). In line with previous evidences, reporting the high ω-
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6/ω-3 fatty acid ratio to be an important player in the pathogenesis of many chronic 
diseases15,16, we found the ratio of ω-6/ω-3  PUFA-derived metabolites significantly increased 
in active patients, versus healthy and resolving biopsies (Figure 1G), thus confirming their 
inflammatory state. Overall, these results point out an impaired ω-3 pro-resolving metabolism 
in the inflamed mucosa, mainly due to a reduction in docosanoids. 
 
MFSD2A in the gut localizes to the vascular endothelium and is up-regulated during 
resolution of intestinal inflammation 
In order to understand the mechanism behind the reduced amount of ω-3 presolving lipid 
mediators observed in patients with active UC, we focused our attention on DHA-metabolism. 
The presence of MFSD2A and its correlation with DHA in the gut has never been 
characterized. Our results showed that in the human large intestine, MFSD2A mainly 
localizes to the endothelium, under both healthy (Supplementary 1C and D) and 
inflammatory conditions (Figure 2A and B), with no expression in other cell types (Figure 2A, 
2B, Supplementary Figure 1C and D). This was confirmed on primary cultures of human 
intestinal microvascular endothelial cells (HIMECs), where the protein localizes to both the 
plasma membrane and the cytoplasm (Supplementary Figure 1C). Moreover, MFSD2A in 
HIMECs mainly co-localize with the endoplasmic reticulum marker Calnexin (Figure 2C).   
We next quantified MFSD2A protein levels in both mucosal extracts and HIMECs of active UC 
patients and healthy subjects (Supplementary Table 2 for patient characteristics). Results 
showed that MFSD2A is up-regulated in the inflamed mucosa, particularly on microvessels, in 
comparison with healthy tissues (Supplementary Figure 1E and F); this was also confirmed 
in UC-HIMECs versus healthy cells (Figure 2D). Interestingly, to verify whether and which 
inflammatory cytokines, known to activate endothelial cells17, and to play a critical role in UC 
pathogenesis18 were able to modulate MFSD2A in the inflammatory milieu, we stimulated 
healthy HIMECs with IL1β, IL17, IL23, TNFα, IL6, and IFNγ. TNFα was the most effective in 
up-regulating MFSD2A, while other interleukins and IFNγ had no effects (Supplementary 
Figure1G). Because of the limited amount of tissue from endoscopic biopsies in remission, 
and the unavailability of surgical specimens from remitting UC patients undergoing surgery for 
other complications, we were unable to isolate HIMECs from subjects with resolution of gut 
inflammation. For this reason, subsequent analyses were performed on whole biopsies. 
Interestingly, MFSD2A was even more upregulated in patients with UC undergoing remission, 
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in comparison with healthy and active tissues (Figure 2E). This suggests an involvement of 
MFSD2A in the resolving phase of intestinal inflammation and raises the question of why 
MFSD2A displays an intermediate expression levels in active tissues, when compared to 
healthy and patients in remission.  
To answer this question, transcript levels of MFSD2A were measured at 2 time points in both 
healthy and UC-HIMECs, upon treatment with TNFα. Results showed that while in healthy 
endothelium MFSD2A is progressively upregulated  by TNFα, in UC-HIMECs the transcript 
levels reached a peak at 8 hours that dropped off after 24 hours of stimulation 
(Supplementary Figure 1H). 
These findings demonstrate not only that inflammatory cytokines such as TNFα directly 
regulate MFSD2A expression, but most importantly that UC-HIMECs display a defect in the 
proper TNFα-dependent modulation of this protein.  
 
MFSD2A overexpression confers anti-angiogenic properties and dampens the TNFα-
induced inflammatory response in HIMECs  
Because MFSD2A is mostly expressed on intestinal endothelial cells, we functionally 
characterized its role on HIMECs, performing gain- and loss-of function studies. Using a 
lentiviral strategy, HIMECs isolated from the intestinal mucosa of healthy surgical resections 
were transduced either with a lentivirus carrying a short hairpin RNA (shRNA) targeting 
MFSD2A (shMFSD2A, Supplementary Figure 2A-C) or a GFP-tagged MFSD2A 
overexpressing vector (MFSD2A-OE, Supplementary Figure 2D-F).  Results showed that 
MFSD2A silencing stimulates in vitro angiogenic properties of HIMECs, in terms of increased 
capillary morphogenesis formation (Figure 3A and B) and growth rate (Figure 3C), 
compared to the scramble control. On the contrary, MFSD2A-OE cells displayed an anti-
angiogenic phenotype (Figure 3D-F), demonstrating a specific role for MFSD2A in regulating 
biological functions of the intestinal endothelium.   
We next wondered whether MFSD2A could influence the response of HIMECs to an 
inflammatory stimulus, such as TNFα. Although MFSD2A expression is increased in patients 
with active UC (see Figure 2D and E) and is upregulated by inflammatory stimuli in healthy 
cells (see Supplementary Figure 1G), MFSD2A silencing exacerbated the endothelial TNFα-
induced response, in comparison with treated control; this was confirmed not only in terms of 
an increase in inflammatory markers, such as IL6, IL1B, IL8, IL18, IL12a, MCP1 and COX218 
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(Supplementary Figure 2G), but also as increased translocation of the P65 subunit of NF-κB 
into the nucleus19 (Supplementary Figure 2H-J). On the contrary, overexpression of 
MFSD2A abated the TNFα-induced inflammatory response, when compared to HIMECs 
carrying the control GFP plasmid (Figure 3G-J). Furthermore, we observed MFSD2A 
modulation to affect in vitro HIMEC permeability, as assessed by transendothelial electrical 
resistance (TEER) measurements (Figure 3K and 3L). Of note, either MFSD2A silencing or 
overexpression did not modify levels of inflammatory cytokines, NF-κB translocation into the 
nucleus and TEER in untreated HIMECs (Figure 3G-L and Supplementary Figure 2G-J). 
Altogether, this data demonstrates that MFSD2A controls the intestinal endothelial response 
to an inflammatory stimulus. 
 
MFSD2A overexpression promotes CYP450-dependent epoxygenation of DHA 
The anti-inflammatory effects elicited by MFSD2A overexpression may be related to its 
capability of interfering with DHA incorporation and/or metabolism. To verify this hypothesis, 
we first analyzed fatty acids in untreated and DHA-treated MFSD2A-OE and silenced 
HIMECs by gas chromatography. The fatty acid profile showed a significant DHA enrichment 
in MFSD2A-OE cells upon treatment with DHA, in comparison with GFP treated HIMECs 
(Figure 4A and B). Conversely, MFSD2A silencing resulted in reduced DHA cell 
incorporation, compared with control (Figure 4A and Supplementary Figure 3A), 
demonstrating an involvement of MFSD2A in the endothelial retention of free DHA. Notably, 
although UC-HIMECs showed increased amounts of MFSD2A versus healthy cells (Figure 
2D), they did not display higher DHA enrichment (Supplementary Figure 3B), suggesting an 
altered MFSD2A capability to increase DHA retention in the active endothelium. 
To understand whether MFSD2A overexpression could also modulate DHA metabolism, we 
next performed a fatty acyl lipidomic analysis on healthy MFSD2A-OE and GFP HIMECs. The 
lipidomic profile revealed that the percentage of DHA-derived metabolites relative to total lipid 
mediators was significantly higher in MFSD2A-OE cells, in comparison with GFP controls 
(Figure 4C and Supplementary Figure 3C). Moreover, a volcano plot showed that the only 
lipid mediators significantly upregulated in MFSD2A-OE cells were those derived from DHA 
(Figure 4D). While AA-derived compounds were significantly reduced in MFSD2A-OE cells 
(Figure 4C, D and Supplementary Figure 3C), mediators derived from other lipid 
precursors, such as EPA, LA, LNA, and DGLA did not change among the two experimental 
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groups (Supplementary Figure 3C). These data indicate that MFSD2A overexpression 
modulates not only DHA retention in HIMECs, but also modifies its metabolism, thus 
mimicking the lipid mediator profile of resolving UC (Figure 1).  
ω-3 DHA, ω-6 AA and other PUFAs can be metabolized by cyclooxygenases (COX), 
lipoxygenases (LOX) and cytochrome P450 (CYP) enzymes to a vast array of biologically 
active oxygenated lipid mediators8,20. The lipidomic profile of healthy MFSD2A-OE and GFP 
HIMECs revealed that among all oxylipins, only CYP450 epoxygenase-derived metabolites of 
DHA and AA were modulated in MFSD2A-OE versus GFP control cells (Figure 4E, F and 
Supplementary Figure 3D and E). CYP450 converts PUFAs to epoxy lipid mediators 
including epoxyeicosatrienoic acids (EpETrEs) derived from AA and epoxydocosapentaenoic 
acids (EpDPEs) from DHA7,8,21. MFSD2A-OE HIMECs showed a decrease in the CYP450-
derived EpETrEs of AA, in comparison with control cells, including their respective hydrolysis 
metabolites, the diols (DiHETrE), which are known to be biologically inactive22 (Figure 4E 
and F). Most importantly we found a significant burst of resolving EpDPEs from DHA in 
MFSD2A-OE cells, compared to GFP controls (Figure 4E and F), indicating that high levels 
of MFSD2A promote CYP450 epoxygenation of DHA and relative resolving oxylipins. Of note, 
the effects of MFSD2A overexpression resembled the conditions observed in the resolving 
mucosa, where the amount of EpDPEs were increased compared to inflamed tissues (Figure 
4G and Supplementary Figure 3F); vice versa, patients with active UC showed a significant 
increase in inflammatory COX- and LOX-derived AA metabolites23, with no changes in CYP-
derived lipid mediators, compared to healthy and patients in remission (Supplementary 
Figure 3G), being consistent with the inflammatory milieu of damaged mucosa. 
Reduced levels of DHA-derived epoxides in active mucosal biopsies compared to healthy 
controls were also observed in UC-HIMECs versus healthy cells (Supplementary Figure 3H 
and I), revealing a selective defect in the endothelial production of EpDPEs. Importantly, this 
defect was not dependent on reduced basal levels of intracellular DHA (see Supplementary 
Figure 3B). Altogether, these findings reveal not only a specific role for MFSD2A in promoting 
DHA accretion and metabolism to EpDPEs in the gut endothelium, but also that these 
capabilities are impaired in the vasculature of active UC patients. 
 
The resolving effects of MFSD2A-OE HIMECs are mediated by the production of 
CYP2C-derived DHA oxylipins 
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The main PUFA-metabolizing CYPs belong to the CYP2 family, in particular the CYP2J and 
CYP2C subfamilies, all localized in the endoplasmic reticulum (ER)24. The CYP2C subfamily 
represents one of the two major pieces of the intestinal P450 pie25. To verify whether the 
beneficial effects exerted by MFSD2A overexpression on HIMECs depends on its capability to 
promote CYP2C-derived metabolites of DHA, we first analyzed whether MFSD2A and CYP2C 
co-localized within the endoplasmic reticulum. The two proteins were indeed found in close 
proximity (Figure 4H), but did not physically interact, as shown by co-immunoprecipitation 
studies (Supplementary Figure 3J). We next inhibited CYP2C enzymes in MFSD2A-OE 
healthy HIMECs using Proadifen hydrochloride, a chemical agent known to be highly 
selective for the CYP-epoxygenase pathway24. Proadifen was able to abate the resolving 
effects exerted by MFSD2A overexpression in TNFα-treated HIMECs, in terms of increased 
TEER (Figure 4I), and higher production of inflammatory cytokines and markers of 
endothelium activation (Figure 4J). Importantly, the reduced amount of EpDPEs observed in 
UC-HIMECs is not due to reduced expression levels of CYP2C (Supplementary Figure 3K), 
or to its enzymatic activity. In fact, epoxy metabolites derived from other lipid precursors, did 
not change between the two groups (Supplementary Figure 3L). Collectively, this data 
demonstrates that MFSD2A controls angiogenic and resolving properties of the gut 
vasculature through modulation of CYP2C-dependent DHA epoxygenation. Consistently, 
when overexpressed in UC-HIMECs, MFSD2A restored not only the defective capability of 
these cells to promote DHA epoxygenation (Supplementary Figure 4A), but also exerted 
anti-inflammatory effects, in terms of reduced in vitro capillary formation (Supplementary 
Figure 4B) and production of inflammatory/angiogenic markers (Supplementary Figure 4C).  
We finally reasoned whether the limited amount of EpDPEs could be responsible for the 
hampered increase of TNFα-induced MFSD2A expression in UC-HIMECs. Experiments 
performed with healthy HIMECs in the presence or absence of Proadifen at 8 and 24 hours of 
TNFα stimulation demonstrated that CYP2C-dependent DHA epoxygenation controls the 
sustained levels of MFSD2A transcripts at later phases (24 hours), whereas is not responsible 
for the early upregulation (8 hours) (Supplementary Figure 4D). 
 
Transplantation of MFSD2A-OE ECFC in combination with DHA administration 
ameliorates DSS-induced acute colitis via CYP2C-dependent EpDPE production 
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The resolution process occurs during the acute phase of inflammation26. For this reason, to 
establish whether MFSD2A overexpression on endothelial cells could promote in vivo the 
resolution of intestinal inflammation, we choose the Dextran Sodium Sulfate (DSS)-induced 
model of acute colitis. Moreover, we took advantage of the capability of human endothelial 
colony-forming cells (ECFCs), to be recruited to ischemic or inflamed tissues27, where they 
remodel the vascular compartment28. We transduced mCherry-tagged human ECFCs with 
MFSD2A-GFP-carrying lentiviral particles (ECFCs-MFSD2A) or GFP-expressing ECFCs 
(ECFCs-GFP), as control. CD1 nude mice undergoing DSS treatment for 6 days were then 
intravenously injected at day 5 with genetically modified ECFCs and monitored for the next 5 
days. To enhance the potential of MFSD2A in promoting resolution of inflammation, parallel 
groups, of either ECFCs-GFP or -MFSD2A transplanted mice were gavaged with ethyl ester 
of DHA or water daily. 
We first verified whether these cells were able to distribute from the peripheral blood to the 
inflamed mucosa of DSS-induced colitic mice29. Intravenously injected mCherry-positive 
human ECFCs (Figure 5A) were indeed shown to home to the inflamed colon of 
immunedeficient mice with colitis (Figure 5B and Supplementary 4E), with cells integrating 
either into pre-existing vessels (Figure 5C) or into perivascular regions (Figure 5D), as 
previously reported for other organs30. Interestingly, ECFCs were found to integrate only into 
blood vessels, and not into lymphatics (Supplementary Figure 4F). Notably, no cell 
engraftment was observed in the intestine of healthy animals (Supplementary Figure 4G). 
FACS analysis on large and small intestines, and on unrelated organs, revealed that while 
ECFCs were detectable at low levels also in the small intestine as well as the liver 2 weeks 
after transplantation, with a progressive decrease at later time points (Supplementary Figure 
5A and B), no cells were found in other unrelated organs at any time point (Supplementary 
Figure 5B). ECFCs were still detectable 6 weeks after injection only in the colon in a small 
percentage (Supplementary Figure 5A and B), indicating that their half-life is limited and 
could be used as a safe therapy. The transduction efficiency was confirmed by increased 
transcript levels of MFSD2A in ECFCs-MFSD2A cells compared to controls (Supplementary 
Figure 5C). 
Only delivery of ECFCs-MFSD2A in combination with DHA significantly reduced the severity 
of colitis, in comparison with the control group (only DSS); this was confirmed in terms of 
Disease Activity Index (DAI)31 (Figure 5E), endoscopic evaluation (Figure 5F and 
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Supplementary Figure 5D), colon length (Supplementary Figure 5E), decreased 
inflammatory markers (Supplementary Figure 5F), and reduced infiltration of neutrophils 
(Supplementary Figure 5G) .  
Angiogenesis, increased expression of adhesion molecules (e.g. VCAM1, MadCam1), 
angiogenic markers (VEGFA, Nos2, Angiopoietin 1), and altered vascular permeability are all 
features of an activated endothelium32, which are also observed during intestinal 
inflammation33. Only delivery of ECFCs-MFSD2A in combination with DHA administration was 
able to reduce the expression levels of these markers (Figure 5G), and only this experimental 
group showed reduced vascular permeability, as revealed by decreased fluorescence 
intensity of Plasmalemmal vesicle-1 (PV1) on endothelial cells34 (Figure 5H and 
Supplementary Figure 5H), and reduced size of hematic vessels (Supplementary Figure 
5I). 
Finally, lipidomic analysis performed on the colons of all experimental groups, showed a 
significant up-regulation of docosanoids only in DHA-fed mice transplanted with ECFCs-
MFSD2A (Supplementary Figure 6A). In these mice, only EpDPEs were found significantly 
increased among all DHA metabolites, with no major modifications for oxylipins derived from 
other PUFAs (Figure 5I and Supplementary Figure 6B-D). Treating mice with Proadifen in 
order to inhibit the production of resolving EpDPEs (Figure 6A and Supplementary Figure 
6E), resulted in the reversion of clinical parameters (Figure 6B and 6C), and anti-angiogenic 
phenotype (Figure 6D and E). Notably, beneficial effects of ECFCs-MFSD2A in DHA-fed 
transplanted mice were retained also in the DSS-induced chronic model of colitis, in terms of 
reduced DAI (Figure 6F), endoscopic score (Figure 6G), low PV-1 expression on endothelial 
cells (Figure 6H) and diminished recruitment of neutrophils in the inflamed colon (Figure 6I), 
compared to the other groups. This is consistent with the fact that ECFCs were still detected 4 
weeks after injection (see Supplementary Figure 5A and B) and support the significance of a 
long-lived effect of ECFCs-MFSD2A cargo on the course of colitis. 
Overall, these findings show that delivery of MFSD2A through a cell-based therapy in 
combination with DHA oral supplementation dampens both acute and chronic colitis via 
production of CYP2C-dependent resolving EpDPEs. Remarkably, administration of single 
EpDPEs did not show any beneficial effects on mice with colitis (Supplementary Figure 7A 
and B).  
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Discussion 
Because the gut is regarded as being in a state of controlled inflammation35, an effective 
resolution program is fundamental to prevent chronic tissue damage, and it is reasonable to 
assume that defective expression of resolving mediators, along with prolonged endothelial 
activation9 may contribute to the chronic inflammatory response associated with UC. Previous 
studies have foreseen this concept, showing lower levels of EPA and DHA lipid precursors 
with higher levels of AA in mucosa of patients with UC36. Here we provide the first evidence 
that patients with active UC fail in producing resolving metabolites derived from DHA 
epoxygenation, and that these lipid mediators are highly present in patients with UC 
undergoing remission, thus revealing their role in the resolution of intestinal inflammation. 
Most importantly, we found that MFSD2A is required for both DHA retention and metabolism 
in the healthy gut vasculature, thus modulating endothelial capabilities to properly respond to 
an inflammatory stimulus; however these functions are impaired in UC-HIMECs, resulting in 
reduced generation of  EpDPEs. 
To date MFSD2A has mostly been studied for its role as transporter of common plasma 
LysoPCs carrying long-chain polyunsaturated fatty acids in the brain, placenta and retina, with 
particular attention to DHA12,14,37. In this work, we show MFSD2A in the gut to be exclusively 
expressed in the endothelium and to control important biological functions of the intestinal 
vasculature, including its ability to mount a proper anti-inflammatory response. Moreover, we 
demonstrate that the generation of EpDPEs and the beneficial effects exerted by MFSD2A 
overexpression, are mediated both in vivo and in vitro by CYP2C, one of the major isoforms 
of the CYP450 family expressed in the intestine25, that co-localize with MFSD2A in the 
endoplasmic reticulum. This is consistent with the notion that ω-3 fatty acids are poor 
substrates of COX and LOX enzymes38, whereas they are highly efficient alternative 
substrates for numerous isoforms of CYP epoxygenases39. 
The interest in ω-3 PUFAs as a source of biosynthetic products during the resolution of 
inflammation has grown tremendously, and their use has been practiced for both prevention 
and treatment of different inflammatory diseases, in animals and humans40.  Nevertheless, 
while few clinical studies involving the administration of DHA and EPA showed some efficacy 
in the course of UC, most of them have given rise to inconclusive or negative results41. Our 
findings provide an explanation for this discrepancy by showing that a selected cohort of not 
responding patients with UC owns a dysfunctional MFSD2A in the gut endothelium.  
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Recent pre-clinical studies have demonstrated that newly identified DHA-derived metabolites 
from LOX enzymatic pathway, such as Maresin 1, Resolvin D2, and aspirin-triggered Resolvin 
D142,43, as well as RvE1 from EPA44,45, are quite effective in preventing intestinal 
inflammation. Unlike these findings, we did not observe beneficial effects with any of the DHA-
derived epoxides used to treat experimental colitis, including treatment with DHA alone. This 
discrepancy may be due to several reasons: 1) a different treatment regimen; while most of 
the studies treat mice with a “prevention” regimen, we administered single  EpDPEs only once 
colitis was fully established; 2) the epoxides we added may have not reached the site of 
action compared to the endogenously generated compounds. While these are theories, the 
fact that DHA metabolites help to reduce inflammation and the only products that are distinctly 
generated are the EpDPEs, strongly argues for their role. 
Notably, we found MFSD2A to be strongly increased by TNFα in healthy HIMECs in two 
distinct phases: an “early phase”, corresponding to the onset of inflammation, where the 
inflammatory milieu containing TNFα triggers MFSD2A expression, and a “late phase”, 
corresponding to the onset of resolution, where MFSD2A-dependent generation of EpDPEs 
not only helps to resolve inflammation, but induces a positive-feedback loop that further 
increases the transcript levels of MFSD2A. In UC-HIMECs this positive loop fails to occur, 
because of the altered capability of MFSD2A in promoting DHA retention and metabolism. 
This might justify why subjects with active UC display intermediate MFSD2A levels compared 
to the other groups, leading to an unsuccessful resolution program (see schematic 
representation in Figure 7A).  
In an attempt to translate our findings into clinical management of UC, we overexpressed 
functional MFSD2A in UC-HIMECs, where it was able to rescue the defective capability of 
these cells in triggering a proper resolution program. Furthermore, we delivered MFSD2A as 
“therapeutic” gene in the DSS-induced experimental models of colitis, using ECFCs. 
Compared with mature endothelial cells that possess limited regenerative capacity46, ECFCs 
are endowed with high proliferative potential and robust vasculogenic properties that render 
these cells a promising opportunity for clinical use47. Our pre-clinical approach allowed 
ECFCs-MFSD2A to increase in situ EpDPE production, which in turn showed inhibitory 
effects on angiogenesis, vascular permeability and expression of inflammatory cytokines, thus 
leading to the clinical amelioration of intestinal inflammation (Figure 7B).  
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The mechanism through which MFSD2A promotes CYP2C-dependent epoxygenation of DHA 
in intestinal endothelial cells needs further investigation. In fact, MFSD2A is not considered a 
transporter of unesterified DHA, but only of DHA-containing lysophosphatidylcholine (LysoPC-
DHA). Our in vitro experiments have been performed using unesterified DHA. We believe free 
DHA may enter the cell via an MFSD2A-independent mechanism48; once inside, it may be 
incorporated into membrane phospholipids of the endoplasmic reticulum49, where MFSD2A in 
close proximity with CYP2C helps this enzyme to metabolize DHA.  
Studies regarding the mechanisms behind the resolution process involved in UC 
pathogenesis are still at their early stages. Our work presents not only the first evidence that 
patients with UC display insufficient production of resolving DHA epoxides, but describes a 
novel, significant role for MFSD2A in the maintenance of an effective resolution program. 
Moreover, we provide not only important insights into the molecular mechanisms regulating 
resolution of intestinal inflammation, but also a strong rationale for the development of novel 
therapeutic strategies to treat UC. Because drug therapy, diet and lifestyle changes do not 
always relieve signs and symptoms of this disease, our cell-based therapeutic approach may 
help a selective cohort of non-responding patients, with the potential advantage of avoiding 
immune suppression, and using natural endogenous pathways to resolve inflammation.  
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Figure Legends 
Figure 1. LC-MS/MS analysis performed on endoscopic mucosal biopsies reveals a 
defined lipid signature in patients with UC.  
(A) Principal component analysis (PCA) of LC-MS/MS data from healthy, active and patients 
in remission (n=9/group).  
(B and C) Volcano plot showing statistical significance (y-axis) as a function of the fold 
change (FC, x-axis) in fatty acid class production of active versus healthy (B) and active 
versus remission (C) (n=9/group).  
(D) Heat map showing significant variations of AA- and DHA-derived metabolites over total 
lipid mediators among healthy, active and patients in remission (n=9/group).  
(E and F) Percentage variations of AA- (E) and DHA- (F) metabolites over total LC-MS/MS-
detected fatty acyl lipids (FA) (n=9/group). 
(G) Ratio of the percentage of ω-6/ω-3 PUFA-derived lipid mediators in healthy, active and 
patients under remission (n=9/group).  
*P < 0,05 and  ***P < 0,005. Data are represented as mean ±s.e.m.  
Figure 2. MFSD2A is exclusively expressed on human gut vasculature and is up-
regulated during remission 
 (A) Representative images (n=5 images/colon) of sectioned human UC colons (n=8 subjects) 
stained for MFSD2A, VE-Cadherin (VE-Cad), α-Smooth Muscle Actin (αSMA), Junction 
adhesion molecule (JAM-A), and DAPI (blue). 
(B) Representative images of tissues described in (A), stained for MFSD2A, CD68, CD11c, 
CD20 and CD3, DAPI (blue).  
(C) Representative confocal images of healthy HIMECs stained for MFSD2A, the 
endoplasmic reticulum marker CALNEXIN and DAPI (blue).  
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(D, top) Western blot analysis of protein extracts from healthy and UC-HIMECs (active) 
(n=5/group). (D, bottom) Representative blots.  
(E, top) Western blot analysis of protein extracts from endoscopic biopsies of healthy (n=4), 
active (n=8) and (n=7) remitting (remission) patients.  
*P < 0,05; **P < 0,01. Scale bars, 50 µm for tissues, and 10 µm for HIMECs. All data are 
represented as mean ±s.e.m.  
Figure 3. MFSD2A modulates angiogenic properties and TNFα-induced response of 
HIMECs 
(A and D) Representative immunofluorescence of transduced HIMECs forming tubules 
stained for DAPI (blue) and GFP (green). Scale bars, 20 µm.   
(B and E) Tubule quantification of shMFSD2A, MFSD2A-OE and relative control HIMECs at 4 
and 6 hours after plating. n=3 replicates/condition/time point of 3 independent experiments.  
(C and F) Proliferation of shMFSD2A, MFSD2A-OE and relative control HIMECs represented 
as optical density versus day 0, at the indicated time points.  n=6 replicates/group of 3 
independent experiments.  
(G) Expression profile of inflammatory markers in untreated and TNFα-stimulated MFSD2A-
OE and relative control HIMECs by qRT-PCR (n=3 replicates/condition of 5 independent 
experiments; # refers to untreated GFP vs TNFα-treated GFP; $ refers to untreated MFSD2A-
OE vs TNFα-treated MFSD2A-OE).  
(H, top) Western blot quantification of NF-κB-p65 subunit in nuclear and cytosolic protein 
extracts of unstimulated and TNFα-treated MFSD2A-OE and GFP HIMECs (n=3 
replicates/condition of 3 independent experiments).  
(H, bottom) Representative blots.  
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(I) Representative immunofluorescence of untreated and TNFα-stimulated MFSD2A-OE and 
GFP control HIMECs stained for NF-κB p65, GFP, and DAPI (blue). Scale bars, 20 µm.  
(J) Quantification of NF-κB p65+ nuclei expressed as percentage over total nuclei (n=3 
replicates/condition of 3 independent experiments).  
(K and L) TEER measurements of TNFα-stimulated shCTRL and shMFSD2A (K) and GFP 
and MFSD2A-OE (L) HIMECs (n=5 replicates/condition of 2 independent experiments).  
*P < 0,05; **P < 0,01; ***P < 0,005; #P < 0,005; $P; < 0,005; &P < 0,005; £P < 0,005. All data 
are represented as mean ±s.e.m.  
Figure 4. MFSD2A overexpression promotes DHA retention and DHA epoxygenation in 
healthy HIMECs 
(A) Graph representing µg of DHA/mg protein in shMFSD2A, MFSD2A-OE and relative 
control HIMECs with or without DHA treatment (n=3 replicates/condition of 2 independent 
experiments).  
(B) Table listing µg of fatty acids/mg protein detected by gas-chromatography of MFSD2A-OE 
and GFP HIMECs with or without DHA (n=3 replicates/condition of 2 independent 
experiments;* refers to DHA-treated vs untreated; # refers to DHA-treated MFSD2A-OE vs 
DHA-treated GFP).  
(C) Lipid composition by LC-MS/MS expressed in percentage of PUFA-derived lipid mediators 
over total fatty acids (FA) in MFSD2A-OE and GFP HIMECs (n=3/group).  
(D) Volcano plot showing statistical significance (y-axis) as a function of the fold change (FC, 
x-axis) in PUFA-derived metabolites of MFSD2A-OE versus GFP HIMECs analyzed by LC-
MS/MS (n=3/group).  
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(E) Heat map showing variations of PUFA-derived metabolites analyzed by LC-MS/MS in 
MFSD2A-OE and GFP control HIMECs (n=3/group). Empty squares represent CYP450-
derived metabolites of AA and DHA.  
(F) Percentage of CYP450-derived metabolites of AA, DHA, EPA and LA over total fatty acids 
(FA) in MFSD2A-OE and GFP HIMECs (n=3/group).  
(G) Percentage of CYP450- and LOX-derived metabolites of DHA over total fatty acids (FA) 
detected by LC-MS/MS in endoscopic mucosal biopsies of healthy, active and remitting 
patients (n=9/group).  
(H) Representative confocal images of healthy HIMECs stained for MFSD2A, CYP2C, and 
DAPI (blue). White arrows indicate co-localization of MFSD2A with CYP2C. Scale bar, 10 µm.  
(I) TEER measurements of TNFα-stimulated MFSD2A-OE and GFP HIMECs with or without 
Proadifen (n=5 replicates of 2 independent experiments).  
(J) Inflammatory cytokine and angiogenic factor expression profile of TNFα-stimulated 
MFSD2A-OE and GFP HIMECs with or without Proadifen by qRT-PCR (n=3 replicates for 2 
independent experiments).  
*P < 0,05; **P < 0,01; ***P < 0,005; #P <0,05. All data are represented as mean ±s.e.m. 
Figure 5. Human ECFCs overexpressing MFSD2A promote in vivo DHA epoxygenation 
and ameliorates DSS-induced experimental colitis 
(A) ECFCs isolated from human blood, and transduced with MFSD2A-OE/mCherry or 
GFP/mCherry control lentiviruses were intravenously injected in CD1 nude mice with colitis.  
(B) Representative pictures of live imaging of a mouse with colitis (left) and isolated colons 
(right) at the indicated conditions one week after injection (n=2 independent experiments with 
5 mice/group). 
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(C and D) 3D reconstruction of immunofluorescence (bottom) of frozen colons from  ECFCs-
GFP/mCherry-injected colitic mice one week after injection, stained for murine CD31 and 
visualized for mCherry (C) and GFP (D). (Top, red cells) Schematic representations of ECFCs  
integrated into mouse pre-existing vessels (C) and perivascular regions (D) (n=2 independent 
experiments with 5 mice/group).  
(E) DAI of ECFCs-MFSD2A-injected DHA-fed colitic mice and control groups (n=2 
independent experiments with 5 mice/group). (* refers to DSS only vs ECFCs-MFSD2A+DHA; 
# refers to ECFCs-MFSD2A vs ECFCs-MFSD2A+DHA; & refers to  ECFCs-GFP+DHA vs 
ECFCs-MFSD2A+DHA).  
(F) Representative endoscopic images (top) and 3D reconstruction of immunofluorescence of 
colons (bottom) stained for murine CD31, GFP-tagged MFSD2A, and DAPI (blue), from 
ECFCs-MFSD2A-injected DHA-fed colitic mice at the indicated conditions 5 days after ECFC 
transplantation.  Scale bars, 10 µm  (n=2 independent experiments with 5 mice/group).  
(G and H) Quantification of angiogenic factors by qRT-PCR (G) and PV-1 mean fluorescence 
intensity (MFI)/vessel area (µm2) (H) in colons of ECFCs-MFSD2A-injected DHA-fed colitic 
mice at the indicated conditions, 5 days after injection  (n=2 independent experiments with 5 
mice/group).  
(I) Heat map showing variation of PUFA-derived lipid mediators detected by LC-MS/MS in 
colon tissues of ECFCs-MFSD2A-injected DHA-fed colitic mice at the indicated conditions 3 
days after ECFC injection (n=3 mice/group representative of 2 independent experiments). 
Empty square indicates CYP450-derived metabolites of DHA.  
*P < 0,05; **P < 0,01; ***P < 0,005; #P < 0,05; ##P < 0,01; &P < 0,05;  &&P < 0,01. All data are 
represented as mean ±s.e.m.  
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Figure 6. CYP2C inhibition abolishes resolving effects of human ECFCs-MFSD2A 
transplantation during experimental colitis  
(A) Heat map showing variations of CYP450-derived metabolites, detected by LC-MS/MS in 
colons of ECFCs-MFSD2A-injected DHA-fed colitic mice at the indicated conditions 3 days 
after injection (n=3 mice/group for 2 independent experiments). Empty square indicates DHA 
epoxides.  
(B) DAI of ECFCs-MFSD2A-injected DHA-fed colitic mice and control groups with or without 
Proadifen administration (n=2 independent experiments with 5 mice per group; * refers to 
DSS only vs ECFCs-MFSD2A+DHA; # refers to ECFCs-MFSD2A vs ECFCs-MFSD2A+DHA; 
& refers to  ECFCs-GFP+DHA vs ECFCs-MFSD2A+DHA; $ refers to ECFCs-MFSD2A+DHA 
vs ECFCs-MFSD2A+DHA with Proadifen. 
(C-E) Colon length (C), inflammatory and angiogenic expression profile by qRT-PCR (D) and 
quantification of PV-1 mean fluorescence intensity (MFI)/vessel area (µm2) (E) of colons from 
ECFCs-MFSD2A-injected DHA-fed colitic mice at the indicated conditions  5 days after ECFC 
injection (n=2 independent experiments with 5 mice/group).  
 (F) DAI of ECFCs-MFSD2A-injected DHA-fed colitic mice and control groups in a DSS-
induced chronic model of colitis. n=2 independent experiments with 5 mice/group; * refers to 
DSS only vs ECFCs-MFSD2A+DHA; # refers to ECFCs-MFSD2A vs ECFCs-MFSD2A+DHA; 
$ refers to  ECFCs-GFP+DHA vs ECFCs-MFSD2A+DHA. 
(G-I) Endoscopic score (G), quantification of PV-1 mean fluorescence intensity (MFI)/vessel 
area (µm2) (H) and Ly6G+ cell infiltration (neutrophils) (I) of colons isolated from ECFCs-
MFSD2A-injected DHA-fed colitic mice at the indicated conditions (n=2 independent 
experiments with 5 mice/group). 
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*P and &P < 0,05; **P < 0,01; ***P < 0,005; #P < 0,05; ##P < 0,01, $P < 0,05, $$P <0,01, $$$P 
<0,005.  All data are represented as ±s.e.m.  
Figure 7. MFSD2A promotes CYP2C-dependent epoxygenation of DHA in endothelial 
cells to generate pro-resolving metabolites and dampen intestinal inflammation 
(A) The inflammatory milieu in the acute phase of patients with UC (a) promotes early 
MFSD2A upregulation. During the onset of resolution (b), MFSD2A efficiently triggers EpDPE 
generation only in patients with UC in remission (green arrow). This leads to late up-
regulation of the protein (yellow arrow), that in turn sustains DHA epoxidation (red arrow) and 
resolution of inflammation (c). In patients with active UC the absence of a positive-feedback 
loop between MFSD2A and DHA epoxides leads to chronic inflammation (d).  
(B) ECFCs-MFSD2A transplanted in mice with colitis, in combination with oral DHA 
administration, home to the inflamed mucosa, integrate either into pre-existing vessels or into 
perivascular regions and promote the release of DHA epoxy metabolites; this stimulates the 
reduction of inflammatory cytokines, angiogenesis and vascular permeability, thus triggering 
the resolution program. (Servier Medical Art, www.servier.com). 
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Supplementary Figure 1. MFSD2A is modulated under inflammatory conditions. Related to Figure 1 and 2. 
(A and B) Percentage variations of EPA- (A) and LNA- (B) derived lipid mediators over total LC-MS/MS-detected fatty acids (FA) (n=9 per group). 
(C and D) Representative immunofluorescence images of cross-sections from human healthy colons stained for MFSD2A, VE-Cadherin (VE-Cad), 
α-Smooth Muscle Actin (αSMA), Junction adhesion molecule (JAM-A) (C), and CD68, CD11c, CD20, CD3 and DAPI (blue) (D). n=5 images per 
colon for 8 patients. (E and F) Representative confocal images of human colonic mucosa from healthy and patients with active UC, stained for 
MFSD2A, VE-Cadherin (VE-Cad), and DAPI (blue) (E) and relative quantification (F) of MFSD2A mean fluorescence intensity (MFI)/per vessel area 
(µm2). n=5 images for n=8 patients per group. (G) MFSD2A transcript fold change relative to untreated upon indicated inflammatory cytokine 
stimulation n=3 per group. (H) MFSD2A transcript levels of healthy and UC-HIMECs relative to GAPDH, upon TNFα stimulation at 0, 8 and 24 
hours. n=3 per group; # refers to untreated active vs untreated healthy. 
*P and  #P < 0,05; **P <0,01; ***P<0,005. All data are represented as mean ±s.e.m. Scale bars 50 µm. 
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Supplementary Figure 2. MFSD2A modulates TNFα-induced response of HIMECs. Related to Figure 3. 
(A) Representative confocal images of shMFSD2A and shCTRL HIMECs stained for MFSD2A, VE-Cadherin (VE-Cad, and DAPI (blue). (B and C) 
Western blot analysis performed on HIMECs transduced with 4 different shRNAs against MFSD2A. Representative bands (B) and quantification of 
MFSD2A silencing (C) in shMFSD2A versus shCTRL cells. shRNA #4 was used for all the subsequent experiments (n=4 lines of HIMECs). (D) 
Representative confocal images of MFSD2A-OE and control GFP HIMECs stained for MFSD2A, VE-Cadherin (VE-Cad), and DAPI (blue). (E) 
Quantification of MFSD2A expression in MFSD2A-OE and GFP HIMECs by qRT-PCR (n=3 group). (F, top) Western blot analysis of MFSD2A 
expression in protein extracts of MFSD2A-OE and GFP HIMECs. β-actin was used as loading control (n=3 group). (F, bottom) Representative 
bands. (G) Expression profile of inflammatory markers in untreated and TNFα-stimulated shMFSD2A and relative control HIMECs by qRT-PCR (n=3 
replicates per condition of 5 independent experiments; # refers to untreated shCTRL vs TNFα-treated shCTRL; $ refers to untreated shMFSD2A vs 
TNFα-treated shMFSD2A; *refers to TNFα-treated shCTRL vs TNFα-treated shMFSD2A). (H) Western blot analysis (top) and representative bands 
(bottom) of the NF-κB-p65 subunit in nuclear and cytosolic protein extracts of unstimulated (UN) and TNFα-stimulated shMFSD2A and shCTRL 
HIMECs. Histone H3 (H3) was used as loading control (n=3 replicates per condition of 3 independent experiments). (I and J) Representative 
immunofluorescence (I) of untreated and TNFα-stimulated shMFSD2A and shCTRL HIMECs stained for NF-κB p65 subunit, GFP, and DAPI (blue) 
and relative quantification (J). Data are expressed as percentage of NFκB p65+ nuclei over the total nuclei (n= 3 replicates per condition of 3 
independent experiments).  
*P < 0,05; **P< 0,1; ***P < 0,005; #P < 0,005, $P < 0,005. All data are represented as mean ±s.e.m.  Scale bars, 10 µm. 
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Supplementary Figure 3. MFSD2A modulates epoxygenation of DHA in HIMECs. Related to Figure  4. 
(A) Table listing µg of fatty acids/mg protein detected by Gas-Chromatography on shMFSD2A and shCTRL control HIMECs with or without DHA 
treatment (n= 5 per group; * refers to +DHA vs untreated; # refers to +DHA-shMFSD2A vs +DHA-shCTRL). (B) DHA/mg protein in healthy and 
active UC-HIMECs with or without DHA treatment (n=5 per group) . (C-E) Percentage of AA-, DHA-, EPA-, LA-, LNA-, DGLA- (C), LOX- (D), and 
COX- (E) derived metabolites over the total fatty acids (FA) analyzed by LC-MS/MS in MFSD2A-OE and GFP HIMECs (n=3 per group). (F) Heat 
map showing significant variations of DHA metabolites classified on the basis of CYP450, and LOX enzymatic pathways in the mucosa of healthy 
patients, patients with UC and patients undergoing remission (n=9 per group). (G) Percentage of CYP450-, LOX- and COX-derived AA metabolites 
over total fatty acids (FA) detected by LC-MS/MS in endoscopic mucosal biopsies of healthy patients, patients with UC and patients undergoing 
remission (n=9 per group). (H) Heat map showing significant variations of DHA metabolites classified on the basis of CYP450, and LOX enzymatic 
pathways in healthy and active UC-HIMECs (n=3 per group). (I) Percentage of CYP450- and LOX-derived DHA metabolites over total fatty acids 
(FA) detected by LC-MS/MS in healthy and active UC-HIMECs (n=3 per group). (J) Co-IP assay by using an anti-GFP antibody of MFSD2A-OE and 
GFP HIMECs. HepG2 cell line was used as positive control for CYP2C (n=2 independent experiments). (K) CYP2C transcript levels quantified by 
qRT-PCR in healthy and  active UC-HIMECs (n=5 per group). (L) Percentage of CYP450-derived metabolites in healthy and active UC-HIMECs 
(n=3 per group). 
*P < 0,05; **P < 0,01; ***P<0,005; #P < 0,05. All data are represented as mean ±s.e.m. 
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Supplementary Figure 4. MFSD2A overexpression corrects UC-HIMECs phenotype. Related to Figure 4 and  5. 
(A) Percentage of CYP450-derived DHA epoxides over total fatty acids (FA) in healthy, UC and MFSD2A-OE UC-HIMECs (n=3 per group). (B) 
Tubule quantification (top) of phase contrast images (bottom) of healthy and UC-HIMECs at 4 hours after plating (n=3 replicates per n=5 
patients/time point). (C) inflammatory marker transcript levels of healthy,  UC active and active MFSD2A-OE UC-HIMECs relative to GAPDH (n=5 
per group). (D) MFSD2A transcript of healthy HIMECs relative to GAPDH, upon TNFα stimulation and Proadifen treatement at the indicated time 
points (n=3 replicates of 2 independent experiments; # refers to 8h-TNFα-treated +Proadifen vs untreated HIMECs). (E) Radiance quantification of 
IVIS live images of colons isolated from colitic mice one week after ECFCs injection, at the indicated conditions (n=5 mice for 2 independent 
experiments). (F) Tridimensional reconstruction of confocal images performed on whole mount staining of colons isolated from ECFCs-
GFP/mCherry-transplanted colitic mice one week after injection, with 2 different z projections (F’ and F’’). Tissues were stained for murine CD31 
(mCD31), Lyve1, mCherry and DAPI (n= 2 independent experiments with 3 mice per group). (G) Representative images of healthy and ECFCs-
GFP/mCherry-transplanted colitic mice one week after injection, using IVIS in vivo imaging system to detect mCherry  (n=5 mice for 2 independent 
experiments).  
*P and #P < 0,05; ***P<0,005; #P < 0,05. All data are represented as mean ±s.e.m. Scale bars, 50 µm. 
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Supplementary Figure 5. ECFC integration into organs progressively decreases over time and ECFCs-MFSD2A-OE transplantation 
combined with DHA administration ameliorates intestinal inflammation in mice. Related to Figure 5. 
(A and B) FACS analysis on colons, intestine, mesenteric lymphnodes (MLNs), liver, lungs, spleens and blood isolated from ECFC-mCherry-injected 
colitic mice at 0 (no ECFCs), 1, 2, 4 and 6 weeks after injection, stained for human CD31 and gated on live cells. Representative density plots (A) 
and relative quantification (B) of mCherry+/hCD31+ ECFCs over live cells in the indicated organs (n=4 mice for each time point). (C) MFSD2A 
transcript levels quantified in ECFCs-MFSD2A and ECFCs-GFP by qRT-PCR (n=3). (D) Endoscopic score of colons from ECFCs-MFSD2A in DHA-
fed transplanted colitic mice  5 days after ECFC injection at the indicated conditions (n=5 mice per group of 2 independent experiments). (E) Colon 
length of ECFCs-MFSD2A-DHA-fed transplanted colitic mice at the indicated conditions 5 days after ECFC injection (n=5 mice per group of 2 
independent experiments). (F) Inflammatory expression profile of colonic mucosa from ECFCs-MFSD2A-DHA-fed transplanted colitic mice at the 
indicated conditions 5 days after ECFC injection (n=5 mice per group of 2 independent experiments). (G) Quantification of Ly6G+ cells (neutrophils) 
infiltration in colonic mucosa of DHA-fed colitic mice transplanted with ECFCs-MFSD2A at the indicated conditions (n=5 mice per group of 2 
independent experiments). (H) Representative confocal images of mouse colons from ECFCs-MFSD2A-DHA-fed transplanted colitic mice at the 
indicated conditions stained for PV-1 and DAPI 5 days after ECFC injection (blue) (n=3 mice for 2 independent experiments). Scale bars, 50 µm. (I) 
Mean diameter quantification of colon vessels after whole mount staining of colitic mice at the indicated conditions 3 days after ECFC injection (n=5-
8  mice per group of 2 independent experiments).  
*P < 0,05 ; **P < 0,01 ; ***P < 0,005. All data are represented as ±s.e.m.  
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Supplementary Figure 6. Transplantation of ECFCs-MFSD2A-OE combined with DHA administration promotes CYP2C-dependent EpDPE 
production. Related to Figure 5 and 6 
(A) Lipidomic analysis performed by LC-MS/MS on the colon extracts of DHA-fed colitic mice transplanted with ECFCs-MFSD2A at the indicated 
conditions, 3 days after ECFC injection. Data are expressed as percentage of the indicated PUFA-derived lipid mediators over total fatty acids (FA) 
(n=3 mice per group of 2 independent experiments). (B-D) Percentage variations of COX- (B), CYP450- (C) and LOX- (D) derived lipid mediators 
over total fatty acids (FA) in DHA-fed colitic mice transplanted with ECFCs-MFSD2A at the indicated conditions by LC-MS/MS analysis (n=3 mice 
per group of 2 independent experiments). (E) Percentage variations of CYP450-derived metabolites over total fatty acids (FA) in DHA-fed colitic 
mice transplanted with ECFCs-MFSD2A at the indicated conditions (n=3 mice per group of 2 independent experiments).  
*P < 0,05; ***P < 0,005. All data are represented as ±s.e.m.  
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A B 
Supplementary Figure 7. Administration of single EpDPEs does not ameliorate intestinal inflammation. Related to Figure 6 
(A and B) DAI (A) and colon length (B) of colitic mice intraperitoneally injected with racemic mixture of the indicated EpDPEs every 
day starting from day 5 after DSS treatmentt (n=of  5 mice per group for 3 independent experiments).  
*P < 0,05; **P < 0,01; ***P<0,005. All data are represented as mean ±s.e.m. 
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 Supplementary Tables 
 
 
 
 
Supplementary Table 1. Characteristics of patients with active UC, UC in remission and healthy 
controls enrolled for endoscopic biopsy collection. Correlation between age/gender and disease status 
was not statistically significant (age-disease linear correlation: r2=0,05421; F=1,433; p-value=0,2425; gender-
disease linear correlation: r2=0,001168; F= 0,02924; p-value=0,8656). 
 
 
Supplementary Table 2. Characteristics of patients with active UC not responding to any treatment 
and control subjects enrolled for immunofluorescence analyses and HIMEC isolation from surgical 
biopsies.  Correlation between age/gender and disease status was not statistically significant (age-disease 
linear correlation: r2=0,2200; F=4,230; p-value=0,0575; gender-disease linear correlation: r2=0,003086; F= 
0,04644; p-value=0,8323). 
 
 
 
  
Sex Age Endoscopic Mayo score Riley index Duration of disease (years) Extent of colitis Therapy in use
F 34 2 3 9 Descending colon, sigma, rectum Steroids
F 56 2 3 N/A Pancolitis Mesalazine
M 33 3 4 9 Pancolitis Anti-Jak
M 49 3 4 18 Descending colon, sigma, rectum Mesalazine
M 40 2 3 5 Pancolitis Mesalazine/Azathioprine
M 42 2 3 16 Descending colon, sigma, rectum Mesalazine
F 68 2 3 12 Descending colon, sigma, rectum Mesalazine
M 52 3 4 24 Descending colon, sigma, rectum Mesalazine
M 57 3 4 12 Descending colon, sigma, rectum Anti-JAK
F 57 0 0 21 Descending colon, sigma, rectum Mesalazine
M 20 0 0 1 Descending colon, sigma, rectum anti-MAdCAM/Azathioprine
F 56 0 0 N/A Pancolitis Mesalazine
M 37 0 0 4 Pancolitis Mesalazine; Infliximab 
M 43 0 0 8 Pancolitis Mesalazine
M 52 0 0 13 Descending colon, sigma, rectum Infliximab
F 30 0 0 15 Descending colon, sigma, rectum Mesalazine
F 70 0 0 26 Descending colon, sigma, rectum Mesalazine/Azathioprine
M 48 0 0 N/A Pancolitis Mesalazine
M 56 / / / Healthy No treatment
M 55 / / / Healthy No treatment
M 39 / / / Healthy No treatment
M 77 / / / Healthy No treatment
F 59 / / / Healthy No treatment
M 79 / / / Healthy No treatment
M 56 / / / Healthy No treatment
M 42 / / / Healthy No treatment
F 45 / / / Healthy No treatment
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Sex Age Duration of disease (years) Extent of colitis Therapy Disease
M 46 18 Pancolitis Steroids/Azathioprine/Mesalazin/Infliximab UC
M 43 20 Descending colon, sigma, rectum Steroids/Azathioprine/Mesalazin/Infliximab UC
M 51 9 Descending colon, sigma, rectum Steroids/Azathioprine/Mesalazin/Infliximab UC
F 68 9 Descending colon, sigma, rectum Steroids/Azathioprine/Mesalazin/Infliximab UC
M 57 7 Pancolitis Steroids/Azathioprine/Mesalazin/Infliximab/Vedulizimab UC
F 70 9 Descending colon, sigma, rectum Steroids/Azathioprine/Mesalazina UC
F 27 3 Descending colon, sigma, rectum Steroids/Infliximab/Azathioprine UC
F 24 4 Descending colon, sigma, rectum Steroids/Mesalazina/Azathioprine UC
M 79 / / No anti-inflammatory therapy Colon cancer
F 73 / / No anti-inflammatory therapy Colon cancer
F 38 / / No anti-inflammatory therapy Colon cancer
M 71 / / No anti-inflammatory therapy Colon cancer
F 73 / / No anti-inflammatory therapy Colon cancer
M 58 / / No anti-inflammatory therapy Colon cancer
M 56 / / No anti-inflammatory therapy Diverticulosis
F 58 / / No anti-inflammatory therapy Polyps
M 61 / / No anti-inflammatory therapy Diverticulosis
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Forward 5'-3' Reverse 5'-3' 
H
u
m
a
n
 
IL1B 
 AGGAGAATGACCTGAGCACC   AGCCTCGTTATCCCATGTGTC 
IL18 TTGCATCAACTTTGTGGCA GCCAAAGTAATCTGATTCC 
IL12A CCTTGCACTTCTGAAGAGATTGA ACAGGGCCATCATAAAAGAGGT 
IL6 AACAAATTCGGTACATCCTCG GCTTTCACACATGTTACTCTTG 
IL8 AACCCTCTGCACCCAGTTTTC TTTTGCCAAGGAGTGCTAAAGA 
COX2 TGGAACGTTGTGAATAACATT GTAAGTTGGTGGACTGTCAATC 
MCP1 AGTCTCTGCCGCCCTTCT GTGACTGGGGCATTGATTG 
CYP2C GAAAGAGCTAACAGAGGATTTG AAAGTGGGATCACAGGGTGAGG  
MFSD2A ACACGCCTTGTTTCCAGGAC GCCAGCAGGTATGCCTTTTG 
MADCAM1 GGGGGCCGCACCTTCCAGCA GTACAGGCCACCTCCGGGTCACC  
GAPDH CATGAGAAGTATGACAACAGC  AGTCCTTCCACGATACCAAAG 
M
o
u
se
 
Angiopoietin 1 TCAGCCTTTGCACTAAAGAAGG  ACAGTCTCGAAATGGTTTCTCT 
Il18 AGCAGTCCCAACTAAGCAGTA   CAGCCAGTAGAGGATGCTGA   
Angiopoietin 2 GGAAACTGACTGATGTGGAAG GAGTCTTGTCGTGTTTAG 
Madcam1 TTCACTGCCAGGTCACCATG GTGAGGTCTGGCTCTGTAG 
Il8 TCGAGACCATTTACTGCAACAG   CATTGCCGGTGGAAATTCCTT   
COX2 CACCCTGACATAGACAGTGAAAG CTGGGTCACGTTGGATGAGG  
Vcam1 TGGTGAAATGGAATCTGAACC CCCAGATGGTGGTTTCCTT 
N o s 2  GTTCTCAGCCCAACAATACAAG GTGGACGGGTCGATGTCAC 
Vegfa TTTACTGCTGTACCTCCACCA ATCTCTCCTATGTGCTGGCTTT 
Il1b AGTTGACGGACCCCAAAA AGCTGGATGCTCTCATCAGG 
Il6 TAGTCCTCCCTACCCCAATTTC TTGGTCCTTAGCCACTCCTTC 
Il12a TCAGAATCACAACCATCAGCA CGCCATTATGATTCAGAGACTG 
Gapdh CGTGTTCCTACCCCCAATGT TGTCATCATACTTGGCAGGTTTCT 
 
Table S3. List of primers used for qRT-PCR 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplemental Experimental Procedures 
 
Patients 
 
For endoscopic biopsies undergoing lipidomic, RNA and protein expression analyses, patients with UC 
undergoing endoscopy were diagnosed by physicians based on clinical, endoscopic and histological criteria. 
Endoscopic activities were assessed using the endoscopic Mayo score (normal: 0=inactive disease; 
erythema/decreased vascular pattern/mild friability/erosions: 1=mild disease; marked erythema/lack of 
vascular pattern/friability: 2=moderate disease; spontaneous bleeding/ulceration: 3=severe disease1, and the 
Riley histological scoring system 2. Active mucosal biopsies were defined by endoscopic Mayo score ≥2 and 
Riley Index≥3; biopsies under remission were defined by Mayo score=0 and Riley Index ≤1. Healthy 
endoscopic biopsies were obtained from patients undergoing routine check-up for non-IBD related diseases.  
Inclusion criteria were: 1) treatment with thiopurines (azathioprine± steroids), monoclonal antibodies and 
enzyme inhibitors (infliximab, vedolizumab, anti-MadCam, anti-JAK); 2) with a balanced mixed Western and 
Mediterranean diet; 2) with moderate or severe illness and decreased food intake. Exclusion criteria were: 1) 
age less than 16 or greater than 80 years; 2) patients taking trace elements (vitamins, fish oil), hypolipemiant 
drugs, or non-steroidal anti-inflammatory drugs in the previous 3 months; 3) patients with associated acute or 
chronic diseases other than IBD that could disturb fatty acid pattern; 4) patients with previous intestinal 
resection; 5) refusal to undergo endoscopic evaluation. All mucosal biopsy samples were snap-frozen and 
stored at –80°C until use (see Supplementary Table 1 for patient characteristics). 
For HIMECs isolation and immunofluorescence analysis, intestinal tissues from involved areas were 
obtained from surgical specimens of patients with active UC not responding to any treatment. Healthy tissues 
from the large intestine of patients admitted for bowel resection due to colon cancer, polyps, or diverticulosis 
were used as controls (see Supplementary Table 2 for patient characteristics). Inclusion and exclusion 
criteria were the same used for endoscopic biopsy selection. 
Samples were not randomized and allocation and evaluation of clinical disease parameters were not blinded. 
The study was approved by the Humanitas Research Hospital ethics committee (Protocol number CE 
Humanitas ex D.M.8/2/2013-183/14). All subjects provided written informed consent.  
Mice 
 
CD1 nude mice (Charles River Laboratories) were maintained in our specific-pathogen free (SPF) animal 
facility and used at 8 weeks of age. All experiments were performed in accordance with the guidelines 
established in the Principle of Laboratory Animal Care (directive 86/609/EEC) and were approved by the 
Italian Ministry of Health. Housing was temperature controlled, with a 12-hour light/12-hour dark cycle. 
Procedures involving mice were conformed to institutional guidelines in agreement with national and 
international law and were approved by the ethics committee of the Humanitas Research Hospital. On the 
basis of our experience with animal models and according to animal-welfare policy (directive 86/609/EEC), 
which strongly suggests the use of a limited number of animals, we estimated that two experiments with n = 
5 mice per group would allow us to reach statistical significance. Mice were not randomized and both 
experimental mice allocation and evaluation of clinical disease parameters were not blinded.  
Liquid Chromatography tandem mass spectrometry (LC-MS/MS) analysis 
Sample preparation. Endoscopic biopsies collected from the colonic mucosa of patients with active UC 
(n=9), UC in remission (n=9), and healthy subjects admitted for routine check-up not due to IBD-related 
symptoms (n=9), were snap frozen in dry ice. HIMECs were maintained in culture for 16 hours with phenol 
red-free DMEM and 0,4% BSA. Cells were then scraped, collected with the respective medium and snap-
frozen in dry ice. For mouse colons, distal and proximal segments, were collected 3 days after ECFC 
injection and immediately snap frozen for lipid extraction. 
 
LC-MS/MS and Lipidomic analysis. Tissue samples and cells were homogenized in phosphate buffer using a 
bead homogenizer (Precellys, Bertin Technologies), with a typical 1:9 ratio of solid sample to buffer. Samples 
(adjusted to a maximum volume of 1-2 ml) were spiked with a mixture of internal standards consisting of 
15(S)-HETE-d8, Leukotriene B4-d4, Resolvin D2-d5, 14(15)-EpETrE-d11, and prostaglandin E1-d4 (5 ng each) 
for recovery and quantitation, and mixed thoroughly. The samples were then extracted for PUFA metabolites 
using C18 extraction columns, as described earlier 3–6. Briefly, the internal standard spiked samples were 
applied to conditioned C18 cartridges, washed with water followed by hexane and dried under vacuum. The 
cartridges were eluted with 0.5 ml methanol. The eluate was then dried under a gentle stream of nitrogen. 
The residue was re-dissolved in 50 µl methanol-25 mM aqueous ammonium acetate (1:1) and subjected to 
LC-MS analysis. HPLC was performed on a Prominence XR system (Shimadzu) using Luna C18 (3µ, 
2.1x150 mm) column. The mobile phase consists of a gradient between A: methanol-water-acetonitrile 
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(10:85:5 v/v) and B: methanol-water-acetonitrile (90:5:5 v/v), both containing 0.1% ammonium acetate. The 
gradient program with respect to the composition of B is as follows: 0-1 min, 50%; 1-8 min, 50-80%; 8-15 
min, 80-95%; and 15-17 min, 95%. The flow rate is 0.2 ml/min. The HPLC eluate was directly introduced to 
ESI source of QTRAP5500 mass analyzer (SCIEX) in the negative ion mode with following conditions: 
Curtain gas, GS1, and GS2: 35 psi, Temperature: 600 ˚C, Ion Spray Voltage: -2500 V, Collision gas: low, 
Declustering Potential: -60 V, and Entrance Potential: -7 V. The eluate was monitored by Multiple Reaction 
Monitoring (MRM) method to detect unique molecular ion – daughter ion combinations for each of the 125 
transitions (to monitor a total of 156 lipid mediators). The MRM was scheduled to monitor each transition for 
120 s around the established retention time for each lipid mediator. Optimized Collisional Energies (18 – 35 
eV) and Collision Cell Exit Potentials (7 – 10 V) are used for each MRM transition. Mass spectra for each 
detected lipid mediator were recorded using the Enhanced Product Ion (EPI) feature to verify the identity of 
the detected peak in addition to MRM transition and retention time match with the standard. The data were 
collected using Analyst 1.6.2 software and the MRM transition chromatograms were quantitated by 
MultiQuant software (both from SCIEX). The internal standard signals in each chromatogram were used for 
normalization for recovery as well as relative quantitation of each analyte.  
 
Isolation, culture and lentiviral transduction of HIMECs 
 
HIMECs were isolated by enzymatic digestion of intestinal mucosal strips, followed by gentle compression to 
extrude endothelial cell clumps, which adhere to fibronectin-coated plates and were subsequently cultured in 
complete Endothelial Cell Growth Medium (EGM, Lonza). After 9 days in culture, cells were enzymatically 
digested (Trypsin, Life Technologies) and incubated with phycoerythrin-conjugated mouse anti-human CD31 
antibody (BD Biosciences, clone WM59), as reported previously7. HIMECs were then sorted on a FACSAria 
IIU (BD Biosciences), using a FACSDiva software (version 6.1.3; BD Biosciences), by positive selection for 
CD31. Cultures of HIMECs were maintained at 37°C in  5% CO2, fed twice a week, and split at confluence. 
They were used between passages 2 and 6.  
Treatments. HIMECs, grown at confluence, were treated with 20 ng/ml of recombinant human TNFα, or IL1-
β, IL-17, IL-23, IL-6, and IFNγ (Peprotech, 300-01A) in EGM for 24 hours and then collected for RNA and 
protein extractions. To evaluate DHA retention by gas chromatography, HIMECs were treated with 10 µM 
DHA (Sigma Aldrich, D2534) in EGM for 16 hours. After incubation, cells were washed with fatty acid free 
0,4%BSA (Sigma Aldrich, A7030) in PBS1x, detached with trypsin and collected for lipid quantification. For 
CYP2C inhibition experiments, HIMECs were treated with or without 30 µM SKF 525-A 8 (Proadifen, ENZO 
life science) in EGM for 24 hours in the presence of  20 ng/ml hTNFα.  
 
Lentiviral transduction. Lentiviral particles production was performed by transient transfection of 293T cells 
according to standard protocols9 and as previously described10. This cell line is competent to replicate 
vectors carrying the SV40 region of replication. It gives high titers when used to produce lentiviruses. It has 
been widely used for lentiviral production, gene expression and protein production.   
Lentiviral vectors were purchased from OriGene (MFSD2A-GFP-tagged, pGFP-C-shLenti MFSD2A and 
scramble). The control plasmid for MFSD2A over-expressing vector, was obtained by excising the MFSD2A 
encoding sequence from the MFSD2A-GFP-tagged lentiviral plasmid and inserting the ATG codon upstream 
the GFP encoding sequence. For MFSD2A silencing, 4 different shRNAs were tested on HIMECs; the most 
efficient in knocking down MFSD2A expression was used for all experiments.  
All cultures were Mycoplasma free. 
 
Tubule Formation, Proliferation, and  Endothelial Cell Permeability assays 
 
HIMEC tube formation was assessed using Matrigel (BD Biosciences), as described previously 10,11. Briefly, 
multi-well dishes were coated with 250 µL of complete medium containing 5 mg/mL Matrigel for 30 minutes 
at 37°C. MFSD2A silenced and MSFD2A-OE HIMECs were seeded in triplicate at a density of 5 × 104 in 
complete EGM. Cells were cultured on Matrigel for 4 and 6 hours, and inverted phase-contrast microscopy 
was used to assess and count endothelial tube-like structures. Five high-power fields per condition were 
examined at 10x magnification. 
For proliferation assay, HIMECs were seeded in 96-well cell culture plates (1 × 103 cells/well) in EGM 
medium. At day 0, 1, 2, 3, and 4 cells were stained with 0.2% crystal violet (Sigma) dissolved in ethanol. 
Uptake of dye by cells on plates was eluted with 33% acetic acid in water. Plates were gently shaken for 20 
min and the absorbance at 595 nm was measured by a Versamax microplate reader (Molecular Devices). 
The optical density of each sample was normalized to day 0 of each samples.  
For cell permeability assay, MFSD2A silenced and MSFD2A-OE HIMECs were seeded on fibronectin-coated 
0.4-µm pore-size Transwell Permeable Supports (Corning Costar, Cambridge, MA), cultured in complete 
culture medium and let to form a monolayer, as described previously 10. After the establishment of a stable 
monolayer, HIMECs were stimulated for 24 hours with 20ng/ml TNFα (Peprotech, 300-01A) and/or with 30 
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µM Proadifen (Enzo Life Science) and assayed for permeability using a Millicall-ERS volt ohm meter (World 
Precision Instruments, New Haven, CT) to measure the transendothelial electrical resistance (TEER). The 
percentage of change in the transendothelial electrical resistance was calculated with respect to TNFα 
treated control cells (GFP or shCTRL).  
 
Gas Chromatography (GC) fatty acid analysis 
 
Cell lipid extraction. Lipids were extracted from 1x106 cells with minor modification of Folch method 12. 
Briefly, cells were homogenized with 500 µl of chloroform/methanol 1:2, centrifuged to recover the lipid 
extract and extracted again two times with chloroform/methanol 2:1, 1:1 (v/v). The total organic phase was 
dried under nitrogen and partitioned with 1 vol of water and 2 vol of chloroform/methanol/water 3/48/47 
(v/v/v) to obtain an organic and an aqueous phase. The organic phase was dried and resuspended in 
chloroform/methanol 2:1, for further analysis. Each solvent used for extraction and analysis contained 
0.045mM 3,5-Di-tert-4-butylhydroxytoluene (BHT) to avoid polyunsaturated fatty acids oxidation. Cell protein 
content was assessed according to Lowry et al. 13. 
 
GC. The fatty acid composition of the organic phase was determined by gas chromatography as  
methylesters 12. Lipids were derivatized with sodium methoxide in methanol 3.33% (w/v) to obtain fatty acid 
methyl esters (FAME). Prior to derivatization a known amount of internal standard (C17:0 triglyceride) was 
added to each sample to correct for yield and recovery of the reaction. FAME were rapidly extracted with 
hexane, dried and resuspended in a known volume of chloroform/methanol prior to injection into a gas 
chromatograph (Agilent Technologies 6850 series II, CA) equipped with flame ionization detector. The 
separation was achieved as follows: capillary column, AT Silar length 30 m, film thickness 0.25 µm; carrier 
gas, helium; injector temperature, 250°C; detector temperature, 275° C. The oven temperature was 
controlled at 50°C for 2 min and then increased at a rate of 10°C min-1 to 200° C, and maintained at t his 
temperature for 20 min. A standard mixture containing all fatty acid methylesters (Sigma Aldrich, MO) was 
injected as calibration for quantitative analysis. The amount of each fatty acid was normalized to protein 
content and expressed as µg/mg protein. 
Immunofluorescence of HIMECs, human and murine colon tissues 
HIMECs were fixed in 4% paraformaldehyde for 20 min at room temperature, washed in PBS1x and 
incubated for 1 hour at room temperature with the Blocking solution (10% goat or donkey serum, 0,1% Triton 
X-100 in PBS1x). HIMECs were then incubated overnight at 4°C with the following antibodies diluted in 
Blocking Solution: anti- VE-Cadherin (1:100, Santa Cruz, sc-6458),  anti-MFSD2A (1:100, Abcam, 
ab105399), anti-GFP (1:500, Life Technologies, A11120),  anti-p65 subunit of NF-κB (1:100, Santa Cruz, sc-
372), anti-CALNEXIN (Blocking solution in 0,3% Triton X-100, 1:100, Santa Cruz, sc-23954),  anti-CYP2C 
(1:200, ThermoFisher, PA5-36232). 
Frozen sections (6 µm) of human and murine colon tissues were fixed in 4% paraformaldehyde solution for 
10 min and then blocked and permeabilized with PBS containing 10% goat or donkey serum, and 0,1% 
Triton X-100  for 1 hr.  After blocking, human colon sections were incubated overnight at 4°C with ant i-VE-
Cadherin (1:100, Abcam, ab7047), anti-αSMA (1:500 , Sigma, a2547); anti-JAM-A (1:50, Thermo Fisher, 36-
1700); anti-MFSD2A (1:100 LsBio, LS-B5348), anti-CD11c (1:500, BD Pharmingen, 550375), anti-CD68 
(1:500, Dako, M 0876), anti-CD20 (1:200, Abcam, ab78237), anti-GFP (1:500, Life Technologies, A6455). 
Mouse colons collected 3 days after ECFC injection, were incubated overnight at 4°C with anti-CD31 (1: 100, 
LS-Bio, LS-B4737); anti-GFP (1:500, Life Technologies, A11120 and A6455), anti-mCherry (1:500, Abcam, 
Ab125096), anti-PV-1 (1:500, BD Pharmingen, 553849) or anti Ly6G (1:200, Abcam, ab25377). 
All sections were then incubated for 1 hour at room temperature with secondary anti-rat, anti-mouse, anti-
rabbit and anti-goat Alexa Fluor 488-conjugated; anti-rabbit, anti-mouse and anti-rat Alexa Fluor 594-
conjugated;  anti-goat, anti-mouse, anti-rat and anti-rabbit Alexa Fluor 647-conjugated antibodies (1:1000, 
Life Technologies), followed by incubation with DAPI for nuclear staining (1:25000, Invitrogen).  
Samples were then washed with PBS1x, mounted with the Fluorescent Mounting Medium (Dako, S302380), 
and analyzed with a laser scanning confocal microscope (FluoView FV1000; Olympus).  
 
Lys6G+ cell quantification. Analysis of Ly6G+ cells on mouse frozen colons were performed on fluorescent 
images acquired at a constant exposure time at ×40 magnification on a laser-scanning confocal microscope 
(FluoView FV1000, Olympus). Five fields for each colon were analyzed. 
 
Immunofluorescence intensity measurements. Analysis of MFSD2A on human frozen colons and PV-1 on 
murine frozen sections were performed on fluorescent images acquired at a constant exposure time at ×20 
magnification on a laser-scanning confocal microscope (FluoView FV1000, Olympus). Colons stained with 
secondary Abs alone were used to set the exposure time. Vascular structures with a lumen were analyzed 
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with ImageJ 1.45, and all images were within a linear intensity range of 0 to 6,231. To exclude nonspecific 
staining, structures less than 8 µm (1 µm = 6.8 pixels) in diameter were excluded. To calculate mean vessel 
intensity, the sums of pixel intensities per vessel were divided by the total vessel area (µm2). The vessel 
mean fluorescence intensity (MFI) from 5 to 10 images per colon (n = 5 mice per experimental group) was 
averaged and compared between healthy and active human tissues for MFSD2A, and treated mice and 
control groups for PV-1.  
Colocalization analysis between MFSD2A and CYP2C, and 3D image reconstruction of frozen sections were 
performed using Imaris Software. 
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR).  
 
RNA was extracted from cells, human and mouse colon tissues using the PureZOL RNA isolation reagent 
(Bio-Rad, Hercules, CA) according to manufacturer’s instructions. RNA retrotranscription was performed with 
High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Carlsbad, CA). Quantitative Real time 
PCR reaction was performed with SYBR® Green Real-Time PCR Master Mix (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. The primer pairs used are summarized in the table below. The 
reactions were performed and analysed on ViiA7 Real-Time PCR System (Applied Biosystems). GAPDH 
expression was used as housekeeping gene. Data were calculated using the 2˄-∆∆Ct method. Primers used 
are summarized in the Table S3. 
 
Western blotting and Co-Immunoprecipitation 
 
Endoscopic biopsies. Mucosal colonic biopsies from healthy patients and patients with active UC  and UC in 
remission recruited as described above, were mechanically homogenized in lysis buffer containing 50 mM 
Tris-HCl, pH 7.4, 1mM ethylenediaminetetraacetic acid, pH 8.0, 150 mM NaCl, 1% Triton X-100, 
supplemented with a cocktail of protease inhibitors (Sigma), for protein extraction. Insoluble material was 
removed by centrifugation for 30 min at 14,000 rpm at 4°C. The concentration of proteins in each lysa te was 
measured using the Bio-Rad protein assay (Bio-Rad Laboratories). 50 µg of protein extracts were separated 
on a 10% polyacrylamide gel and electrotransferred to a nitrocellulose membrane (Bio-Rad Laboratories). 
Nonspecific binding was blocked with Tris-buffered saline containing 5% non-fat dried milk and 0.1% Tween 
20, followed by overnight incubation at 4°C with an ti-human MFSD2A (1:1000, Abcam, ab105399), anti-
human β-ACTIN (1:1000, Santa Cruz, sc-1615). Membranes were washed for 1 hour with Tris-buffered 
saline containing 0.1% Tween 20 and then incubated for 1 hour with the appropriate horseradish peroxidase-
conjugated secondary antibody (1:3000; GE Healthcare). The membranes were then incubated with 
Immobilon Western Chemilum (Millipore) for 1 minute, after which bands were detected by Chemidoc (Bio-
Rad Laboratories), using Quantity One software. MFSD2A quantification was done by ImageJ 1.45 software 
using the anti-βACTIN detected bands as- normalizer. 
 
HIMECs. Control and genetically modified cells with the indicated treatments and at the indicated time points 
were lysed with extraction buffer containing 50 mM Tris-HCl, pH 7.4, 1mM ethylenediaminetetraacetic acid, 
pH 8.0, 150 mM NaCl, 1% Triton X-100, supplemented with a cocktail of protease inhibitors (Sigma). The 
protein concentration of lysates, and immunoblotting was performed as described above, using the following 
primary antibodies: anti-human MFSD2A (1:1000, Abcam, ab105399), and anti-human β-ACTIN (1:1000, 
Santa Cruz, sc-1615), as loading control.  
 
Co-Immunoprecipitation. For co-immunoprecipitation of MFSD2A with CYP2C, GFP and GFP-tagged 
MFSD2A-OE cells were grown at confluence on 100 mm Petri dishes cells. 2,5x106 cells per condition were 
detached, collected and resuspended in lysis buffer containing Tris–HCl 50 mM, pH 8.0, NaCl 150 mM, and 
1% NP-40 supplemented with protease and phophatase inhibitors (cOmplete™, Sigma-Aldrich) for 20 
minutes, and then centrifuged for 15 min at 18,000 g at 4°C.  Cell extracts were then pre-cleared with lysis 
buffer-containing protein-G agarose beads for 1 hour at 4°C. Pre-cleared lysates (1 mg) were incubated  with 
an antibody against GFP (1 µg/ml in lysis buffer; Life Technologies, A11120) overnight at 4°C. After washing 
with lysis buffer, the immunoprecipitates were resuspended in SDS-sample buffer and immunoblotted, as 
described above. Nitrocellulose membranes were incubated with anti-human MFSD2A (1:1000, Abcam, 
ab105399), and  anti-human CYP2C (1:1000, ThermoFisher, PA5-36232). Protein extracts from Human liver 
carcinoma cells (HepG2) were used as positive control for CYP2C. 
 
For nuclear protein extraction, 200.000 control and genetically modified HIMECs with the indicated 
treatments were washed with ice-cold PBS1x and incubated for 5 min in ice with 200 µl of L1 lysis buffer 
containing 50mM Tris-HCl pH 8, 2 mM EDTA pH8, 0,1% NP-40, and 10% Glycerol. After scraping and 
centrifugation for 3’ at 2000 rpm at 4°C, supernata nts, composed of cytoplasmic proteins, were collected. 
The pellet, containing the nuclear fraction,  was resuspended in buffer C (500mM KCl, 10% Glycerol, 25mM 
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HEPES pH 7,8). Both protein fractions were analyzed by western blot, as described above. Membranes were 
incubated with anti-human NFkB p65 subunit (1:1000, Santa Cruz, sc-372) and anti-hystone H3, gently 
provided by Dr. Chiara Porta (Humanitas Research Institute, Milan, Italy).  The nuclear fraction was 
normalized on anti-hystone H3 detected band. 
 
Induction and evaluation of colonic inflammation 
For the DSS-induced acute colitis model, 8-week-old female mice were subjected to 1 oral cycle of 2% DSS 
(molecular mass, 40 kDa; MP Biomedicals) in drinking water for 6 days followed by 4 days in regular water. 
In this model, the disease activity index (DAI), recorded daily starting from day 0 to day 10, is based on the 
evaluation of different parameters characterizing experimental colitis induction and progression. Body weight, 
presence of gross blood in the feces, and stool consistency were recorded at the indicated time points. 
According to the criteria proposed by Cooper et al.14, the DAI was determined by scoring changes in: weight 
loss (0 = none, 1 = 1%–5%, 2 = 5%–10%, 3 = 10%–20%, 4 = >20%); stool consistency (0 = normal, 2 = 
loose, 4 = diarrhea); and rectal bleeding (0 = normal, 2 = occult bleeding, 4 = gross bleeding). A 5-point (0-4) 
DAI was thus obtained.  
 
Endoscopic damage assessment. For monitoring of colitis, a high resolution mouse video endoscopic system 
was developed and used as previously described7.  
 
Adoptive transfer of engineered ECFCs, mice treatments and in vivo imaging.  
Endothelial cells forming colony (ECFCs) were isolated and characterized as previously described by 
Colombo et al.15. Peripheral blood mononuclear cells (PBMCs) were isolated by gradient centrifugation, 
resuspended in EGM-2 medium (Lonza), and seeded onto human fibronectin (Sigma Aldrich)-coated 24-well 
plates. Non-adherent cells and debris were aspirated after one day of culture; adherent cells were washed 
and cultured in EGM-2 medium. ECFC colonies, identified by visual inspection using an inverted microscope, 
were detached from the original tissue culture plates by trypsinization (Euroclone) and replated onto 6-well 
tissue culture plates previously coated with type-I collagen (Corning Inc). ECFCs were maintained in EGM-2 
medium at 37°C in 5% CO2, fed three times a week, a nd split at confluence. ECFC phenotype was 
confirmed by flow cytometry, by assessing the expression of the endothelial markers CD31, KDR and 
CD146, while lacking the hematopoietic markers CD45 and CD14. 
ECFCs were then transduced with MFSD2A-GFP-tagged and GFP control scramble lentiviruses (OriGene). 
The GFP control plasmid for MFSD2A over-expressing vector, was obtained by excising the MFSD2A 
encoding sequence from the MFSD2A-GFP-tagged lentiviral plasmid and inserting the ATG codon upstream 
the GFP encoding sequence. Both ECFCs overexpressing MSFD2A (ECFCs-MFSD2A) and control ECFCs 
(ECFCs-GFP) were double infected with mCherry lentiviral particles to monitor ECFC homing into the 
inflamed mucosa by live imaging analysis. The mCherry lentiviral vector was kindly provided by Dr. Marco 
Erreni, Humanitas Clinical and Research Center, Milan, Italy.  
For DSS-induced acute colitis, mice were administered with 2% DSS for 6 days. At day 5 of DSS 
administration, mice were injected in the tail vein with 5x105 ECFCs-GFP or ECFCs-MFSD2A and at the 
same time were administered with 1mg/g/mouse DHA-ethyl-ester (Cayman chemical) by oral gavage every 
day until sacrifice. In parallel, at day 5 of DSS a group of DHA-fed ECFCs-MFSD2A injected mice was 
intraperitoneally treated  with 30mg/kg of Proadifen16, every day until sacrifice.  
In another set of experiments the following metabolites were intravenously injected (0,05 mg/Kg)17 every day 
until sacrifice, starting at day 5 of DSS administration: ±10(11)-EpDPE, ±13(14)-EpDPE, ±16(17)-EpDPE, 
±19(20)-EpDPE, ±7(8)-EpDPE (Cayman Chemical). 
Mice were sacrificed 3 and or 5 days after ECFCs injection and/or DHA and Proadifen administration, when 
differences among groups reached the highest statistical significance, upon endoscopic evaluation. Colons 
were immediately frozen in dry ice for RNA extractions, and LC-MS/MS analysis or embedded in Cryoblock 
Compound for immunofluorescence studies. For long-term studies, mice were sacrificed 4 and 6 weeks after 
ECFCs transplantation. Two independent experiments of DSS-induced chronic colitis were performed with 
mixed cages of mice all derived from the same SPF source and with 2 different lots of DSS. Mice were  
treated according to the following scheme: 6 days of DSS, 1 week of water and finally, 6 days of DSS, 1 
week of water and finally DSS until sacrifice at day 35 for tissue analysis. At day 5 of the first abnd second 
cycle, mice were injected with ECFCs and/or administered with DHA-ethyl-ester.  
In vivo imaging was performed to confirm ECFCs engraftment and homing to the inflamed mucosa, before 
and after the sacrifice on the whole mouse and isolated colons respectively, using a Caliper Xenogen IVIS 
Spectrum (Caliper Life Sciences, Hopkinton, MA). A light image was obtained for anatomical orientation and 
mCherry fluorescence was detected using standard parameters, which include 12.9-cm field of view to 
observe 3 mice simultaneously, excitation filter = 570 nm, emission filter = 620 nm, f-stop 1, pixel binning 8, 
and 0.5 seconds exposure time. Images were analyzed using Living Imaging software and the region of 
interest (ROI) function. For in vivo imaging quantification, the radiance (p/sec/cm2/sr) of the ROI was 
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automatically calculated by the Caliper Xenogen IVIS Spectrum Software. Three ROIs for each colon where 
used for calculating the average of radiance. 
 
FACS analysis of mCherry-ECFCs-injected colitic mice 
Nude CD1 colitic mice were injected with 5x105 mCherry transduced ECFCs at day 5 of 2% DSS treatment. 
Not-injected colitic mice were used as controls. Mice were sacrificed 1, 2 4 and 6 weeks after ECFC 
injection. Organs were isolated and processed for the FACS.  
 
Lungs, livers and lymphnodes were disrupted through a 70 µm filter (BD Falcon) with a 1 ml syringe plunger 
and washed with 10 ml of RPMI medium supplemented with 10% foetal calf serum and 20 mM Hepes. Lungs 
and livers were then centrifuged at 800 rpm for 10 minutes to discard debris. Ammonium-Chloride-Potassium 
(ACK) lysis buffer was used directly on pellets to remove red blood cells. All samples were washed with 
RPMI medium and centrifuged. Samples were then suspended in PBS and counted.  
 
Colon and small intestines were cleaned with HBSS solution containing antibiotics and Hepes, and cut in 
small pieces. The epithelial layer was removed by incubating the intestine fragments with HBSS and EDTA 
solution at 37°C under gentle agitation. Intestine fragments deprived from epithelial cells were chopped and 
digested with HBSS containing 5% foetal calf serum, Hepes, CaCl2, dispase and collagenase (Roche) and 
DNase at 37°C under agitation. Digested fragments w ere further disrupted through a 100 µm filter (BD 
Falcon) with a 1 ml syringe plunger and washed with 10 ml of RPMI medium supplemented with 10% foetal 
calf serum and 20 mM Hepes. Single cell suspension was further filtered over a 70 µm filter (BD Falcon). 
Blood was collected from mouse cheeks and collected in EDTA tubes (Greiner Mini Collect). 100 µl of blood 
was briefly lysed with 500 µl of ACK lysis buffer and washed with 1ml RPMI medium supplemented with 10% 
foetal calf serum and 20 mM Hepes.  
Cell suspension from all organs were stained with LIVE/DEAD® Cell Stain Kit (Life Technologies),  washed in 
PBS and analyzed by FACS (BD FACSCanto™ II - BD Biosciences). Data analysis was performed by 
FlowJo v10 software.  
 
Whole Mount Staining and morphometric analysis of colonic vessels 
Three days after ECFC injection, mice were anesthetized with 100 mg/kg ketamine and 50 mg/kg xylazine, 
and 10 mL of 1% paraformaldehyde fixative solution was perfused into the heart. Colons were removed from 
untreated and injected mice with the indicated treatments, and immersed in 1% paraformaldehyde fixative 
solution, overnight at 4°C. Tissues were then washe d and incubated with hamster anti-CD31 (1:500; 
Millipore, MAB1398Z), rabbit anti-Lyve1 (1:500, Abcam, ab14917), rat anti-mCherry (1:500, ThermoFisher 
Scientific, M11217) antibodies diluted in PBS containing 0.3% Triton X-100, 2% bovine serum albumin, 5% 
goat serum, 0.01% glycine, and 0.1% sodium azide, overnight at 4°C. Anti-hamster Alexa Fluor 488, anti -
rabbit Alexa Fluor 647 (1:500; Molecular Probes) and anti-rat Alexa Fluor 594 (1:500; Molecular Probes) 
were used as secondary antibodies, and incubated overnight at 4°C. Samples were then mounted with 
Vectashield (Vector Laboratories, Burlingame, CA) and imaged with a laser scanning confocal microscope 
(Fluoview FV1000; Olympus). Fluorescent images were acquired at a constant exposure time at 20× or 60× 
magnification on a laser scanning confocal microscope (FluoView FV1000; Olympus). Morphometric analysis 
of colon whole mounts was performed by 3D visualization of both hematic and lymphatic vessels. Images 
were taken as a z series stack using a ×10 objective and analyzed by Imaris Bitplane software, thus allowing 
visualization of the vessels in the submucosal and serosal-muscular layers. For each colon analyzed (n = 5–
8 mice for each experimental group), both hematic and lymphatic vessel size were measured in 10 randomly 
chosen regions covered by vessels (each 1.0 mm2 in area) and were represented as the mean value of 
diameters (µm). 
 
Statistics 
The sample size was calculated on the basis of the effect size derived from preliminary data. Normal 
distribution and source of variation were calculated automatically for every statistical comparison. Mean 
comparisons were calculated accordingly. Statistical analyses were performed with either Microsoft Excel or 
IBM SPSS and Graph Pad 5-Prism statistical packages. Data were represented as means ±s.e.m. Mean 
comparisons between two experimental conditions were analyzed with 2-tailed unpaired Student’s t test. For 
three or more conditions, One-way ANOVA with Bonferroni’s correction was used. Two-way ANOVA with 
Bonferroni’s correction was used for the statistical analysis of DAI (in DSS-induced colitis experiments). P-
values lower than or equal to 0.05 were considered statistically significant. Heatmap of data distributions 
were displayed with GENE-E software from Broad Institute (https://software.broadinstitute.org/GENE-E/). 
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